Skip to main content
SpringerLink
Log in

Pretibial Myxedema (Thyroid Dermopathy)

  • Chapter
Thyroid Disorders with Cutaneous Manifestations

Editorial Perspective

Pretibial myxedema (thyroid dermopathy) is the sine qua non of the dermatologic manifestations of thyroid disease. Although any medical student can reflexively state that pretibial myxedema is a hallmark of Graves disease, how many clinicians realize that the term is a misnomer? That thyroid dermopathy is not necessarily limited to the pretibial region and is not exclusively seen in patients with Graves disease are just two facts frequently misconceived about this condition. The reality is that much has been learned about the immunologic pathogenesis of thyroid der- mopathy, a condition that results from the accumulation of the glycosaminoglycans, hyaluronic acid, and chondroitin sulfate in the dermis. A precise understanding of its pathogenesis, however, remains to be determined. This chapter surveys the clinical, biological, and therapeutic landscape of thyroid dermopathy. By understanding its natural history, eliminating or reducing predisposing factors such as smoking and obesity, appreciating the complexities of the immunologic aberrations leading to mucin deposition, and having a logical approach to therapy, clinicians should be able to at least ameliorate this chronic, occasionally severe, recalcitrant disorder.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Busuttil BE, Frauman AG. Extrathyroidal manifestations of Graves' disease: the thyrotropin receptor is expressed in extraocular, but not cardiac, muscle tissues. J Clin Endocrinol Metab 2001;86:2315–2319.

    Article  PubMed  CAS  Google Scholar 

  2. Bahn RS. Understanding the immunology of Graves' ophthalmopathy. Is it an autoimmune disease? Endocrinol Metab Clin North Am 2000;29:287– 296.

    Article  CAS  Google Scholar 

  3. Fatourechi V. Pretibial myxedema—pathophysiol-ogy and treatment options. Am J Clin Dermatol 2005;6:295–309.

    Article  PubMed  Google Scholar 

  4. Bartley GB, Fatourechi V, Kadmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284–290.

    PubMed  CAS  Google Scholar 

  5. Garrity JA, Fatourechi V, Bergstralh EJ, et al. Results of transantral orbital decompression in 428 patients with severe Graves' ophthalmopathy. Am J Ophthalmol 1993;116:533–547.

    PubMed  CAS  Google Scholar 

  6. Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine 1994;73:1–7.

    Article  PubMed  CAS  Google Scholar 

  7. Peacey SR, Flemming L, Messenger A, Weetman AP. Is Graves' dermopathy a generalized disorder? Thyroid 1996;6:41–45.

    Article  PubMed  CAS  Google Scholar 

  8. Noppakun N, Bancheun K, Chandraprasert S. Unusual locations of localized myxedema in Graves' disease. Report of three cases. Arch Dermatol 1986;122:85–88.

    Article  CAS  Google Scholar 

  9. Singh SP, Ellyin F, Singh SK, Yoon B. Elephantiasislike appearance of upper and lower extremities in Graves' dermopathy. Am J Med Sci 1985;290:73–76.

    Article  PubMed  CAS  Google Scholar 

  10. Forgie JC, Highet AS, Kelly SA. Myxoedematous infiltrate of the forehead in treated hypothyroidism. Clin Exp Dermatol 1994;19:168–169.

    Article  PubMed  CAS  Google Scholar 

  11. Wortsman J, Dietrich J, Traycoff RB, Stone S. Preradial myxedema in thyroid disease. Arch Dermatol 1981;117:635–638.

    Article  PubMed  CAS  Google Scholar 

  12. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves' disease. Thyroid 2000;10:685–692.

    Article  PubMed  CAS  Google Scholar 

  13. Fatourechi, V, Ahmed DDF, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab 2002;87:5435–5441.

    Article  PubMed  CAS  Google Scholar 

  14. Anderson CK, Miller OF. Triad of exophthalmos, pretib-ial myxedema, and acropachy in a patient with Graves' disease. J Am Acad Dermatol 2003;48:970–972.

    Article  PubMed  Google Scholar 

  15. Fatourechi V. Pretibial myxedema: pathophysiology and treatment options. Am J Clin Dermatol 2005; 6:295–309.

    Article  PubMed  Google Scholar 

  16. Kiljanski J, Nebes V, Stachura I, Kennerdell JS, Wall JR. Should Graves' disease be considered a collagen disorder of the thyroid, skeletal muscle and connective tissue? Horn Metab Res 1995;27(12):528–532.

    Article  CAS  Google Scholar 

  17. Schwartz KM, Fatourechi V, Ahmned DD, et al. Extensive personal experience: dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab 2002;87:438–446.

    Article  PubMed  CAS  Google Scholar 

  18. 18.Garrity JA, Bahn RS: Pathogenesis of Graves' oph-thalmopathy: implications for prediction, prevention, and treatment. Am J Ophthalmol 2006;142:147–153.

    Article  PubMed  CAS  Google Scholar 

  19. Bahn RS. Pathophysiology of Graves' ophthalmopa-thy: the cycle of disease. J Clin Endocrinol Metab 2003;88:1939–1946.

    Article  PubMed  CAS  Google Scholar 

  20. Smith TJ. The putative role of fibroblasts in the patho-genesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity 2003;36:409–415.

    Article  PubMed  CAS  Google Scholar 

  21. Smith TJ: Fibroblast biology in thyroid diseases. Curr Opin Endocrinol Diabetes 2002;9:393–400.

    Article  CAS  Google Scholar 

  22. Bahn RS. Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003;88:1939–1946.

    Article  PubMed  CAS  Google Scholar 

  23. Fatourechi V, Bartley GB, Eghbali-Fatourechi GZ, et al. Graves' dermopathy and acropachy are markers of severe Graves' ophthalmopathy. Thyroid 2003;13:1141–1144.

    Article  PubMed  Google Scholar 

  24. Gleeson H, Kelly W, Toft A, et al. Severe thyroid eye disease associated with primary hypothy-roidism and thyroid-associated dermopathy. Thyroid 1999;9:1115–1118.

    Article  PubMed  CAS  Google Scholar 

  25. Morris JC, Hay ID, Nelson RE, Jiang NS. Clinical utility of thyrotropin-receptor antibody assays: comparison of radioreceptor and bioassay methods. Mayo Clin Proc 1988;63:707–717.

    Article  PubMed  Google Scholar 

  26. Siegler M, Refetoff S. Pretibial myxedema—a reversible cause of foot drop due to entrapment of the pero-neal nerve. N Engl J Med 1976;294:1383–1384.

    Article  PubMed  CAS  Google Scholar 

  27. Kato N, Ueno H, Matsubara M. A case report of EMO syndrome showing localized hyperhidrosis in pretibial myxedema. J Dermatol 1991;18:598–604.

    PubMed  CAS  Google Scholar 

  28. Gitter DG, Sato K. Localized hyperhidrosis in pretibial myxedema. J Am Acad Dermatol 1990 23 (2 pt 1):250–254.

    Article  PubMed  CAS  Google Scholar 

  29. Terheyden, P, Kahaly GJ, Zillikens D, Brocker EB. Lack of response of elephantiasic pretibial myxo-edema to treatment with high-dose intravenous immu-noglobulins. Clin Exp Dermatol 2003;28:224–226.

    Article  PubMed  CAS  Google Scholar 

  30. Susser WS, Heermans AG, Chapman MS, Baughman RD. Elephantiasic pretibial myxedema: a novel treatment for an uncommon disorder. J Am Acad Dermatol 2002;46:723–726.

    Article  PubMed  Google Scholar 

  31. Sharma VK, Sood A, Singh M. Elephantiasic pretib-ial myxedema in Graves' disease. J Assoc Physicians India 2002;50:1430–1431.

    PubMed  CAS  Google Scholar 

  32. Cohen JB, Wapnir I, McDougal IR. Elephantiasic pretibial myxedema. Thyroid 2004;14:237–238.

    Article  PubMed  Google Scholar 

  33. Akasu F, Takazawa K, Akasa R, Onaya T. Localized myxedema on the nasal dorsum in a patient with Graves' disease: report of a case. J Endocrinol Invest 1989;12:717–721.

    PubMed  CAS  Google Scholar 

  34. Davies TF. Trauma and pressure explain the clinical presentation of the Graves' disease triad. Thyroid 2000;10:629–630.

    Article  PubMed  CAS  Google Scholar 

  35. Wright AL, Buxton PK, Menzies D. Pretibial myxedema localized to scar tissue. Int J Dermatol 1990;29:54–55.

    Article  PubMed  CAS  Google Scholar 

  36. Pujol RM, Monmany J, Bagué S, Alomar A. Graves' disease presenting as localized myxoedematous infiltration in a smallpox vaccination scar. Clin Exp Dermatol 2000;25:132–134.

    Article  PubMed  CAS  Google Scholar 

  37. Tong DW, Ho KK. Pretibial myxoedema presenting as a scar infiltrate. Australas J Dermatol 1998;39:255–257.

    Article  PubMed  CAS  Google Scholar 

  38. Kind R, Hornstein OP. Clinical picture of pretibial myxedema and new aspects of diagnosis and patho-genesis. Hautarzt 1976;27:375–381.

    PubMed  CAS  Google Scholar 

  39. Vanhoenacker FM, Pelckmans MC, DeBeuckeleer LH, et al. Thyroid acropachy: correlation of imaging and pathology. Eur Radiol 2001;11:1058–1062.

    Article  PubMed  CAS  Google Scholar 

  40. Anderson CK, Miller OF 3rd. Triad of exoph-thalmos, pretibial myxedema, and acropachy in a patient with Graves' disease. J Am Acad Dermatol 2003;48(6):970–972.

    Article  PubMed  Google Scholar 

  41. Capsoni F, Minonzio F, Sarzi-Puttini P, et al. Thyroid acropachy: an unusual rheumatic manifestation of Graves' disease. Clin Exp Rheumatol 2005;23:125–126.

    PubMed  CAS  Google Scholar 

  42. Asai S, Asada K, Miyachi H. Clubbed fingers in a patient with inflammatory gingival hyperplasia. Intern Med 2005;44:1307–1311.

    Article  PubMed  Google Scholar 

  43. Tran HA. Thyroid acropachy. Intern Med J 2004;34:513–514.

    Article  PubMed  CAS  Google Scholar 

  44. Galinat S, Archambeaud F, Fronty S. Thyroid acropachy following radioiodine therapy. Endocr J 2000;47(suppl):116.

    Google Scholar 

  45. Rothschild BM, Yoon BH. Thyroid acropachy complicated by lymphatic obstruction. Arthritis Rheum 1982;25:588–590.

    Article  PubMed  CAS  Google Scholar 

  46. Goette DK. Thyroid acropachy. Arch Dermatol 1980;116:205–206.

    Article  PubMed  CAS  Google Scholar 

  47. Kinsella RA Jr, Back DK. Thyroid acropachy. Med Clin North Am 1968;52:393–398.

    PubMed  Google Scholar 

  48. Ekmekci T, Ucak S, Sakiz D. Investigation of the presence of acropachy in patients with autoimmune thyroid diseases. Endocrinologist 2007;17:23–25.

    Article  Google Scholar 

  49. Seigel RS, Thrall JH, Sisson JC.99 mTc-pyrophos-phate scan and radiographic correlation in thyroid acro-pa chy: case report. J Nucl Med 1976;17:791–793.

    PubMed  CAS  Google Scholar 

  50. Bahn RS, Garrity JA, Bartley GB, Gorman CA. Diagnostic evaluation of Graves' ophthalmopathy. Endocrinol Metab Clin North Am 1988;17:527–545.

    PubMed  CAS  Google Scholar 

  51. Bartley GB, Gorman CA. Diagnostic criteria fo rGraves' ophthalmopathy. Am J Ophthalmol 1995; 119:792–795.

    PubMed  CAS  Google Scholar 

  52. Marcocci C, Bartelena L, Bogazzi F, et al. Studies on the occurrence of ophthalmopathy in Graves' disease. Acta Endocrinol 1989;120:473–478.

    Article  PubMed  CAS  Google Scholar 

  53. Bartley GB, Fatourechi V, Kadmas EF, et al. The incidence of Graves' ophthalmopathy in Olmsted County, Minnesota. Am J Ophthal 1995;120:511–517.

    PubMed  CAS  Google Scholar 

  54. Mourits MP, Koomneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989;73:639–644.

    Article  PubMed  CAS  Google Scholar 

  55. Fatourechi V, Garrity JA, Bartley GB, et al. Graves' ophthalmopathy. Results of transantral orbital decompression performed primarily for cosmetic indications. Ophthalmology 1994;101:938–942.

    CAS  Google Scholar 

  56. Omohundro C, Dijkstra JW, Camisa C, Bergfeld WF. Early onset pretibial myxedema in the absence of ophthalmopathy: a morphologic evolution. Cutis 1996;58:211–214.

    PubMed  CAS  Google Scholar 

  57. Georgala S, Katoulis AC, Georgala C, et al. Pretibial myxedema as the initial manifestation of Graves' disease. J Eur Acad Dermatol Venereol 2002;16:380–383.

    Article  PubMed  CAS  Google Scholar 

  58. Cho S, Choi JH, Sung KJ, et al. Graves' disease presenting as elephantiasic pretibial myxedema and nodules of the hands. Int J Dermatol 2001;40:276–277.

    Article  PubMed  CAS  Google Scholar 

  59. Bartley GB, Fatourechi V, Kadrmas EF, et al. Chronology of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:426–434.

    PubMed  CAS  Google Scholar 

  60. Matsuoka LY, Wortsman J, Uitto J, et al. Altered skin elastic fibers in hypothyroid myxedema and pretibial myxedema. Arch Intern Med 1985;145:117–121.

    Article  PubMed  CAS  Google Scholar 

  61. Konrad K, Brenner W, Pehamberger H. Ultrastructural and immunological findings in Graves' disease with pretibial myxedema. J Cutan Pathol 1980;7:99–108.

    Article  PubMed  CAS  Google Scholar 

  62. Somach SC, Helm TN, Lawlor KB, et al. Pretibial mucin. Histologic patterns and clinical correlation. Arch Dermatol 1993;129:1152–1156.

    Article  CAS  Google Scholar 

  63. Fujita H, Asagami C, Suetoni Y, et al. Study on the ultrastructure and mucin production in pretibial myxedema. Acta Pathol Jpn 1971;21:207–230.

    PubMed  CAS  Google Scholar 

  64. Nakagawa K, Ishii M, Hamada T, Oohasi, M. Electron microscopic studies of pretibial myxoedema using ruthenium red staining. Nippon Hifuka Gakkai Zasshi 1984;94:1141–1148.

    PubMed  CAS  Google Scholar 

  65. Ishii M, Nakagawa K, Hamada T. An ultrastructural study of pretibial myxedema utilizing improved ruthenium red stain. J Cutan Pathol 1984;11:125–131.

    Article  PubMed  CAS  Google Scholar 

  66. Bull RH, Coburn PR, Mortimer PS. Pretibial myxo-edema: a manifestation of lymphoedema? Lancet 1993;341:403–404.

    Article  PubMed  CAS  Google Scholar 

  67. Ban Y, Davies TF, Greenberg DA, et al. Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease. Genes Immunol 2003;4:586–593.

    Article  CAS  Google Scholar 

  68. Davies TF, Greenberg D, Tomer Y. The genetics of the autoimmune thyroid diseases. Ann Endocrinol 2003;64:28–30.

    CAS  Google Scholar 

  69. Villanueva R, Inzerillo AM, Tomer Y, et al. Limited genetic susceptibility to severe Graves' ophthal-mopathy: no role for CTLA-4 but evidence for an environmental etiology. Thyroid 2000;10:791–798.

    Article  PubMed  CAS  Google Scholar 

  70. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and oph-thalmopathy. Endocr Rev 2003;24:802–835.

    Article  PubMed  CAS  Google Scholar 

  71. Weetman AP. Graves' disease by any other name? Thyroid 2000;10:1071–1072.

    Article  PubMed  CAS  Google Scholar 

  72. Ludgate M, Baker G. Inducing Graves' ophthal-mopathy. J Endocrinol Invest 2004;27:211–215.

    PubMed  CAS  Google Scholar 

  73. Zhang L, Baker G, Janus D, et al. Biological effects of thyrotropin receptor activation on human orbital prea-dipocytes. Invest Ophthalmol Vis Sci 2006;47:5197–5203.

    Article  PubMed  Google Scholar 

  74. Aniszewski JP, Valyasevi RW, Bahn RS. Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy. J Clin Endocrinol Metab 2000;85:776–780.

    Article  PubMed  CAS  Google Scholar 

  75. Gerding MN, van der Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy. Clin Endocrinol 2000;52:267–271.

    Article  CAS  Google Scholar 

  76. Heufelder AE, Bahn RS. Modulation of cellular functions in retroorbital fibroblasts using antisense oligonucleotides targeting the c-myc protooncogene. Invest Ophthalmol Vis Sci 1995;36:1420–1432.

    PubMed  CAS  Google Scholar 

  77. Horvat A, Grims R, Korsic M. Tonometry in the diagnosis of subclinical ophthalmopathy in patients with Basedow's disease. Lijec Vjesn 1991;113:10–12.

    PubMed  CAS  Google Scholar 

  78. Salvi MG, Neri F. Thyroid ophthalmopathy. Curr Ther Endocrinol Metab 1994;5:77–81.

    PubMed  CAS  Google Scholar 

  79. Ando T, Latif R, Davies TF. Thyrotropin receptor antibodies: new insights into their actions and clinical relevance. Best Pract Res Clin Endocrinol Metab 2005;19:33–52.

    Article  PubMed  CAS  Google Scholar 

  80. Stadlmayr W, Spitzweg C, Bichlmain AM, Heufelder AEL TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves' ophthalmopathy and pretib-ial myxedema. Thyroid 1997;7:3–12.

    Article  PubMed  CAS  Google Scholar 

  81. Heufelder AE, Dutton CM, Sakar G, et al. Detection of TSH receptor RNA in cultured fibroblasts from patients with Graves' ophthalmopathy and pretibial dermopathy. Thyroid 1993;3:297–300.

    Article  PubMed  CAS  Google Scholar 

  82. Daumerie C, Ludgate M, Costogiola S, Many MC. Evidence for thyrotropin receptor immunoreactiv-ity in pretibial connective tissue from patients with thyroid-associated dermopathy. Eur J Endocrinol 2002;146:35–38.

    Article  PubMed  CAS  Google Scholar 

  83. Metcalfe RA, Davies R, Weetman AP. Analysis of fibroblast-stimulating activity in IgG from patients with Graves' dermopathy. Thyroid 1993;3:207–212.

    Article  PubMed  CAS  Google Scholar 

  84. Cheung HS, Nicoloff JP, Kamile MB, et al. Stimulation of fibroblast biosynthetic activity by serum of patients with pretibial myxedema. J Invest Dermatol 1978;71:12–17.

    Article  PubMed  CAS  Google Scholar 

  85. Smith TJ. Insights into the role of fibroblasts in human autoimmune diseases. Clin Exp Immunol 2005;141:388–397.

    Article  PubMed  CAS  Google Scholar 

  86. Koumas L, Smith TJ, Phipps RP. Fibroblast subsets in the human orbit: Thy-1(+) and Thy-1(−) subpopu-lations exhibit distinct phenotypes. Eur J Immunol 2002;32:477–485.

    Article  PubMed  CAS  Google Scholar 

  87. Smith TJ, Koumas L, Gagnon A, et al. Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2002;87:385–392.

    Article  PubMed  CAS  Google Scholar 

  88. Shishiba Y, Imai Y, Odajinma R, et al. Immunoglobulin G of patients with circumscribed pretibial myxedema of Graves' disease stimulates proteoglycan synthesis in human skin fibroblast in culture. Acta Endocrinol 1992;127:44–51.

    PubMed  CAS  Google Scholar 

  89. Shishiba Y, Takeuchi Y, Yokoi N, Ozawa Y, Shimizy TT. Thyroid hormone excess stimulates the synthesis of proteoglycan in human skin fibroblasts in culture. Acta Endocrinol (Copenh) 1990;123:541–549.

    CAS  Google Scholar 

  90. Shishiba Y, Tananka T, Ozawa Y, Shimuzu T, Kadowaki N. Chemical characterization of high buoyant density proteoglycan accumulated in the affected skin of pretibial myxedema of Graves' disease. Endocrinol Jpn 1986;33:395–403.

    Article  PubMed  CAS  Google Scholar 

  91. Kahaly G, Forster G, Hansen C. Glycosaminoglycans in thyroid eye disease. Thyroid 1998;8:429–432.

    Article  PubMed  CAS  Google Scholar 

  92. Bahn RS. TSH receptor expression in orbital tissue and its role in the pathogenesis of Graves' ophthal-mopathy. J Endocrinol Invest 2004;27:216–220.

    PubMed  CAS  Google Scholar 

  93. Korducki JM, Loftus SJ, Bahn RS. Stimulation of glycosaminoglycan production in cultured human retroocular fibroblasts. Invest Ophthalmol Vis Sci 1992;33:2037–2042.

    PubMed  CAS  Google Scholar 

  94. Rapoport B, Alsabeh R, Aftergood D, McLachlan SM. Elephantiasic pretibial myxedema: insight into and a hypothesis regarding the pathogenesis of the extrathyroidal manifestations of Graves' disease. Thyroid 2000;10:685–692.

    Article  PubMed  CAS  Google Scholar 

  95. Schwartz KM, Ahmed DD, Ahmed I, Fatourechi V. Development of localized myxedema in a skin graft. Int J Dermatol 2002;41:401–403.

    Article  PubMed  Google Scholar 

  96. Missner SC, Ramsay EW, Houck HE, Kauffman CL. Graves' disease presenting as localized myxe-dema in a thigh donor graft site. J Am Acad Dermatol 1998;39(5 pt 2):846–849.

    Article  PubMed  CAS  Google Scholar 

  97. Cawood TJ, Moriarty P, O'Farrelly C, O'Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J Clin Endocrin Metab 2007;92:59–64.

    Article  CAS  Google Scholar 

  98. Hegedius L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthal-mopathy. J Endocrinol Invest 2004;27:265–271.

    PubMed  CAS  Google Scholar 

  99. Krassas GE, Wiersinga W. Smoking and autoimmune thyroid disease: the plot thickens. Eur J Endocrinol 2006;154:777–780.

    Article  PubMed  CAS  Google Scholar 

  100. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current versus lifetime cigarette consumption. Clin Endocrinol 1996;45:477–481.

    Article  CAS  Google Scholar 

  101. Tallstedt L, Lundell G, Taube A. Graves' ophthal-mopathy and tobacco smoking. Acta Endocrinol 1993;129:147–150.

    PubMed  CAS  Google Scholar 

  102. Shine B, Fells P, Edwards OM, Weetman AP. Association between Graves' ophthalmopathy and smoking. Lancet 1990;335:1261–1263.

    Article  PubMed  CAS  Google Scholar 

  103. Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA 1993;269:479–482.

    Article  PubMed  CAS  Google Scholar 

  104. Bartalena L. Smoking and Graves' disease. J Endocrinol Invest 2002;25:402.

    PubMed  Google Scholar 

  105. Metcalfe RA, Weetman AP. Stimulation of extraoc-ular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol 1994;40:67–72.

    Article  CAS  Google Scholar 

  106. Mack WP, Stasior GO, Cao HJ, Stasior OG, Smith TJ. The effect of cigarette smoke constituents on the expression of HLA-DR in orbital fibroblasts derived from patients with Graves ophthalmopathy. Ophthal Plast Reconstr Surg 1999;15:260–271.

    Article  PubMed  CAS  Google Scholar 

  107. Hofbauer LC, Mühlberg T, König A, et al. Soluble interleukin-1 receptor antagonist serum levels in smokers and nonsmokers with Graves' ophthal-mopathy undergoing orbital radiotherapy. J Clin Endocrinol Metab 1997;82:2244–2247.

    Article  PubMed  CAS  Google Scholar 

  108. Kim KJ, Kim HH, Chang SE et al. A case of pretib-ial mucinosis without thyroid disease. J Dermatol 2002;29:383–385.

    PubMed  Google Scholar 

  109. Harris JE, Purcell SM, Griffin TD. Acral persistent papular mucinosis. J Am Acad Dermatol 2004;51:982–988.

    Article  PubMed  Google Scholar 

  110. McNeill AM, Barr RJ. Scleromyxedema-like fibro-mucinosis in a patient undergoing hemodialysis. Int J Dermatol 2002;41:364–367.

    Article  PubMed  Google Scholar 

  111. Rongioletti F. Scleromyxedema: a potentially disabling and fatal disease. Giornale Italiano di Dermatologia e Venereologia 2000;135:323–328.

    Google Scholar 

  112. Lo P Y, Tzung TY. Lichen myxedematosus in a patient with hepatocellular carcinoma. Br J Dermatol 2000;143:452–453.

    Article  PubMed  CAS  Google Scholar 

  113. Yamazaki S, Katayama I, Satoh T, Yokozeki H, Nishioka K. Acral ichthyosiform mucinosis in association with Sjogren's syndrome: a peculiar form of pretibial myxedema? J Dermatol 1993;20:715–718.

    PubMed  CAS  Google Scholar 

  114. Jackson EM, English JC 3rd. Diffuse cutaneous mucinoses. Dermatol Clin 2002;20:493–501.

    PubMed  Google Scholar 

  115. Poswig A, Hinrichs R, Megahed M, et al. Discrete papular mucinosis-a rare subtype of lichen myxo-edematosus. Clin Exp Dermatol 2000;25:289–292.

    Article  PubMed  CAS  Google Scholar 

  116. Neudecker BA, Stern R, Mark LA, Steinberg S. Scleromyxedema-like lesions of patients in renal failure contain hyaluronan: a possible pathophysiological mechanism. J Cutan Pathol 2005;32:612–615.

    Article  PubMed  Google Scholar 

  117. Kucher C, Xu X, Pasha T, Elenitsas R. Histopathologic comparison of nephrogenic fibrosing dermopathy and scleromyxedema. J Cut Pathol 2005;32:484–490.

    Article  Google Scholar 

  118. Dawn G, Holmes SC. Scleromyxoedema-like eruption following haemodialysis or nephrogenic fibrosing dermopathy? Br J Dermatol 2004;150:167–168.

    Article  PubMed  CAS  Google Scholar 

  119. Chung HJ, Chung KY. Nephrogenic fibrosing der-mopathy: response to high-dose intravenous immu-noglobulin. Br J Dermatol 2004;150:596–597.

    Article  PubMed  Google Scholar 

  120. Streams BN, Liu V, Liegeois N, Moschella SM. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 2003;48:42–47.

    Article  PubMed  Google Scholar 

  121. Mackay-Wiggan JM, Cohen DJ, Hardy MA, Knobler EH, Grossman ME. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003;48:55–60.

    Article  PubMed  Google Scholar 

  122. Baron PW, Cantos K, Hillebrand DJ, et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003;25:204–209.

    Article  PubMed  Google Scholar 

  123. Launay D, Hatron P Y, Delaporte E, et al. Scleromyxedema (lichen myxedematosus) associated with dermatomyosi-tis. Br J Dermatol 2001;144:359–362.

    Article  PubMed  CAS  Google Scholar 

  124. Pomann JJ, Rudner EJ. Scleromyxedema revisited. Int J Dermatol 2003;42:31–35.

    Article  PubMed  Google Scholar 

  125. Durani BK, Kurzen H, Hartschuh W, Naeher H. Koebner phenomenon due to scratch test in sclero-myxoedema. Br J Dermatol 2001;145:306–308.

    Article  PubMed  CAS  Google Scholar 

  126. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves' oph-thalmopathy. Ann Intern Med 1998;129:632–635.

    PubMed  CAS  Google Scholar 

  127. Rotman-Pikielny P, Brucker-Davis F, Turner ML, Sarlis NJ, Skarulis MC. Lack of effect of long-term octreotide therapy in severe thyroid-associated der-mopathy. Thyroid 2003;13:465–470.

    Article  PubMed  CAS  Google Scholar 

  128. Wiersinga WM. Preventing Graves' ophthalmopa-thy. N Engl J Med 1998;338:121–122.

    Article  PubMed  CAS  Google Scholar 

  129. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494–497.

    Article  PubMed  CAS  Google Scholar 

  130. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733–1738.

    Article  CAS  Google Scholar 

  131. Tallstedt L, Lundell G. Radioiodine treatment, ablation, and ophthalmopathy: a balanced perspective. Thyroid 1997;7:241–245.

    Article  PubMed  CAS  Google Scholar 

  132. Torring O, Tallstedt L, Wallin G, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine—a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab 1996;81:2986–2993.

    Article  CAS  Google Scholar 

  133. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338:73–78.

    Article  PubMed  CAS  Google Scholar 

  134. Marcocci C, Bartalena L, Tanda ML, et al. Graves' ophthalmopathy and I-131 therapy. Q J Nucl Med 1999;43:307–312.

    PubMed  CAS  Google Scholar 

  135. DeGroot LJ. Radioiodine and the immune system. Thyroid 1997;7:259–264.

    Article  PubMed  CAS  Google Scholar 

  136. Menconi F, Marino M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidec-tomy alone on mild to moderate Graves' orbitopa-thy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007;92:1653–1658.

    Article  PubMed  CAS  Google Scholar 

  137. Vana S, Nemec J, Rezek P, Novak Z. Treatment of endocrine orbital disease by elimination of the thyroid gland. The effect of unsuccessful elimination, severe pretibial myxedema and persistence of hypothyroidism after removal in long-term results. Vnitr Lek 1998;44:387–390.

    CAS  Google Scholar 

  138. Moleti M, Mattina F, Salamone I, et al. Effects of thyroidectomy alone or followed by radioiodine ablation of thyroid remnants on the outcome of graves' ophthalmopathy. Thyroid 2003;13:653–658.

    Article  PubMed  Google Scholar 

  139. Fatourechi V. Medical treatment of Graves' ophthalmop-athy. Ophthalmol Clin North Am 2000;13:683–691.

    Article  Google Scholar 

  140. Wiersinga WM. Management of Graves' oph-thalmopathy. Nat Clin Pract Endocrinol Metab 2007;3:396–404.

    Article  PubMed  CAS  Google Scholar 

  141. Bartalena L, Marcocci C, Tanda ML, et al. An update on medical management of Graves' ophthalmopathy. J Endocrinol Invest 2005;28:469–478.

    PubMed  CAS  Google Scholar 

  142. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989;321:1353–1359.

    Article  PubMed  CAS  Google Scholar 

  143. Antonelli A, Navarranne A, Palla R, et al. Pretibial myxedema and high-dose intravenous immunoglob-ulin treatment. Thyroid 1994;4:399–408.

    Article  PubMed  CAS  Google Scholar 

  144. Baschieri L, Antonelli A, Nardi S, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves' ophthalmopathy. Thyroid 1997;7:579–585.

    Article  PubMed  CAS  Google Scholar 

  145. Kahaly GJ, Bang H, Berg W, Dittmar M. Randomized trial of intravenous immunoglobulins versus prednisolone in Graves' ophthalmopathy. Clin Exp Immunol 1996;106:197–202.

    Article  PubMed  CAS  Google Scholar 

  146. Wiersinga WM. Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid 1992;2:229–233.

    Article  PubMed  CAS  Google Scholar 

  147. Glinoer D, Schrooyen M, Winand R. Plasma exchange therapy for severe Graves' ophthalmopa-thy. Dev Ophthalmol 1989;20:91–93.

    PubMed  CAS  Google Scholar 

  148. Glinoer D. The role of plasmapheresis in Graves' oph-thalmopathy. Exp Clin Endocrinol 1991;97:328–331.

    Article  PubMed  CAS  Google Scholar 

  149. Marcocci C, Bartalena L, Marino M, et al. Current medical management of Graves ophthalmopathy. Ophthal Plast Reconstr Surg 2002;18:402–408.

    Article  PubMed  Google Scholar 

  150. Chiu CS, Rubin PAD. Pharmacotherapies and nonpharmacotherapies for orbital inflammatory disease. Int Ophthalmol Clin 2004;44:165–185.

    Article  PubMed  Google Scholar 

  151. Noppen M, Velkeniers B, Steenssens L, Vanhaelst L. Beneficial effects of plasmapheresis followed by immunosuppressive therapy in pretibial myxedema. Acta Clin Belg 1988;43:381–383.

    PubMed  CAS  Google Scholar 

  152. Kung AW, Michon J, Tai KS, Chan FL. The effect of somatostatin versus corticosteroid in the treatment of Graves' ophthalmopathy. Thyroid;1996;6:381–384.

    Article  PubMed  CAS  Google Scholar 

  153. Krassas GE. Somatostatin analogues in the treatment of thyroid eye disease. Thyroid 1998;8:443–435.

    Article  PubMed  CAS  Google Scholar 

  154. Gullu S, Gurses MA, Baskal N, et al. Effect of octreotide treatment on Graves' ophthalmopathy. Endocr J 1999;46:573–577.

    Article  PubMed  Google Scholar 

  155. Bartalena L, Marcocci C, Pinchera A. Somatostatin analogs for Graves' ophthalmopathy: do they bounce off like a rubber bullet? J Clin Endocrinol Metab 2004;89:5908–5909.

    Article  PubMed  CAS  Google Scholar 

  156. Krassas GE. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004;27:281–287.

    PubMed  CAS  Google Scholar 

  157. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005;90:841–848.

    Article  PubMed  CAS  Google Scholar 

  158. Stan MN, Garrity JA, Bradley EA, et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves' ophthalmopathy. J Clin Endocrinol Metab 2006;91:4817–4824.

    Article  PubMed  CAS  Google Scholar 

  159. Kriss JP. Pathogenesis and treatment of pretibial myxedema. Endocrinol Metab Clin North Am 1987;16:409–415.

    PubMed  CAS  Google Scholar 

  160. Kriss JP, Pleshakov V, Rosenblum A, Sharp G. Therapy with occlusive dressings of pretibial myxe-dema with fluocinolone acetonide. J Clin Endocrinol Metab 1967;27:595–604.

    Article  PubMed  CAS  Google Scholar 

  161. Volden G. Successful treatment of chronic skin diseases with clobetasol propionate and a hydro-colloid occlusive dressing. Acta Derm Venereol 1992;72:69–71.

    PubMed  CAS  Google Scholar 

  162. Parker LN, Wu SY, Lai MK, et al. The early diagnosis of atypical thyroid acropachy. Arch Intern Med 1982;142:1749–1751.

    Article  PubMed  CAS  Google Scholar 

  163. Engin B, Gümüsel M, Ozdemir M, Cakir M. Successful combined pentoxifylline and intralesional triamcinolone acetonide treatment of severe pretibial myxedema. Dermatol Online J 2007;13:16.

    PubMed  Google Scholar 

  164. Antonelli A, Palla R, Casarosa L, et al. In vitro sol-ubilization of deposits of IgG immune complexes by gamma-globulins in patients with Graves' disease, Graves' ophthalmopathy, pretibial myxo-edema and Hashimoto's thyroiditis. Pharmacol Res 1992;26(suppl 2):170–171.

    Article  PubMed  Google Scholar 

  165. Antonelli A, Saracino A, Alberti B, et al. High-dose intravenous immunoglobulin treatment in Graves' ophthalmopathy. Acta Endocrinol 1992;126:13–23.

    Article  PubMed  CAS  Google Scholar 

  166. Felton J, Derrick EK, Price ML. Successful combined surgical and octreotide treatment of severe pretibial myxoedema reviewed after 9 years. Br J Dermatol 2003;148:825–826.

    Article  PubMed  CAS  Google Scholar 

  167. Kuyvenhoven JP, van der Pijl JW, Goslings BM, Wiersinga WM. Graves' dermopathy: does octre-otide scintigraphy predict the response to octreotide treatment? Thyroid 1996;6:385–389.

    Article  PubMed  CAS  Google Scholar 

  168. Priestley GC, Aldridge RD, Sime PJ, Wilson D. Skin fibroblast activity in pretibial myxoedema and the effect of octreotide (Sandostatin) in vitro. Br J Dermatol 1994;131:52–56.

    Article  PubMed  CAS  Google Scholar 

  169. Pingsmann A, Ockenfels HM, Patsalis T. Surgical excision of pseudotumorous pretibial myxedema. Foot Ankle Int 1996;7:107–110.

    Google Scholar 

  170. Shaw SJ, Kamdar V, Bughi S. Elephantiasic form of severe pseudotumorous pretibial myxedema: a case report. Endocrinologist 2000;10:433–436.

    Article  Google Scholar 

  171. Derrick EK, Tanner B, Price ML. Successful surgical treatment of severe pretibial myxoedema. Br J Dermatol, 1995;133:317–318.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, MN, USA

    Vahab Fatourechi MD

Authors
  1. Vahab Fatourechi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School at Camden, Marlton, NJ, USA

    Warren R. Heymann MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Fatourechi, V. (2008). Pretibial Myxedema (Thyroid Dermopathy). In: Heymann, W.R. (eds) Thyroid Disorders with Cutaneous Manifestations. Springer, London. https://doi.org/10.1007/978-1-84800-187-9_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-84800-187-9_10

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84800-186-2

  • Online ISBN: 978-1-84800-187-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation